

Act, 2013, the Company is which dividends has not been demat account of Investor Authority). Hence, all such med for the last 7 years from it account of IEPF Authority. pective shareholders at their ny, whose dividends are lying the dividends expeditiously. lio number / demat account w.r.pricol.com for information rs.

s during the last seven years imited, 109, Race Course, o.in", for making a valid claim ase no valid claim has been aspect of which the dividends erred to the demat account of

I mandatory requirement for F Authority, the Company will share certificate against such t such demat shares. In case es after transfer to the demat n can be made to the IEPF the Ru and the same is

For Pricol Limited
T.G.Thamizhanban
Company Secretary

E-TENDER NOTICE

E-tenders are invited from Authorized Suppliers / Manufacturers in TWO BID system for the supply of **05 STs of 66 KV Isolator**. Tenders can be submitted only by online through the portal www.etenders.kerala.gov.in.

Tender No. : **TTP/CD/ELE/TM/224/2019-2020** dated **02.05.2019**. Tender ID : **2019-TTPL_276730_1**

Due date: **11.06.2019 upto 12 Noon.**
Sd/- HOD(Commercial)

Publishing of tender in e-procurement portal	31.05.2019 @ 17:00 hrs
Pre-Bid Meeting Date	10.06.2019 @ 11:00 hrs at CMRL Office-Admin Building, Koyambedu.
Date and Time of Submission of Bid in e-portal	28/06/2019 up to 15:00 hours (IST)
Date & Time of Opening of Technical Bids in online	01/07/2019 at 15:05 hours (IST)
CMRL invites e-tender on single stage two packet system (Technical and Financial) only through e-procurement bids on National Competitive Bidding for "Tender for Licensing of Kiosk Spaces in Selected Elevated and UG at street level Metro Stations along Corridor - I & II of Phase-I". For complete details, please visit e-procurement (CPP Portal) website: http://eprocure.gov.in/eprocure/app	
Any Corrigendum / Addendum to this publication, if any, would appear only on above mentioned website and will not be published in newspapers.	
Tender Authority : Chief General Manager (P&BD), Chennai Metro Rail Limited, Admin Building, CMRL Depot, Poonamallee High Road, Koyambedu, Chennai - 600 107 Phone : 044-2379 2000 www.chennaiemr.orail.org	
DIPR/1656/Tender/2019	Chief General Manager (P&BD)

**DELHI JAL BOARD: GOVT. OF N.C.T. OF DELHI
OFFICE OF THE EXECUTIVE ENGINEER (NWR) II
H-BLOCK; SECTOR-15: ROHINI: DELHI-110089
PH: 27851040 (E-MAIL eenw2.djb@gmail.com)**

Press Notice No. 05 (2019-20)

Press Notice Tender

S. No.	Name of work	Amount put to Tender	Earnest Money/ Tender Fee	Date of release of tender procurement solution/I.D. No.	Last date/time of receipt of bid through e-procurement solution
1.	Construction of 25 MLD Wastewater Treatment for Rejuvenation of Timarpur oxidation pond using Phytorid Technology with natural sustainable treatment process.	Item Rate	Rs. 68,63,681/- Rs. 1500/-	22.05.2019 2019_DJB_172536_1	21.06.2019 Upto 3.00 PM

Further details in this regard can be seen at <https://govtprocurement.delhi.gov.in>

Issued by P.R.O. (Water)

Advt. No. J.S.V. 005/2019-20

Executive Engineer (NWR)

MITED

Fax: 033-24015556
om

(₹ in Lakhs)		
March, 2019		
CONSOLIDATED		
Year Ended	Year Ended	
31.03.2018	31.03.2019	31.03.2018
(Audited)	(Audited)	(Audited)
0,872.43	2,28,753.90	2,06,787.45
9,901.09	20,233.22	21,242.63
5,663.73	14,887.14	16,613.97
5,606.30	15,057.21	16,439.69
2,225.27	2,225.27	2,225.27
7.05	6.68	7.34

their respective meetings held on
negating ₹ 2678.41 lacs, (including

& Equipment from written down
affected by a change in accounting
cause the straight-line method will
depreciation of ₹ 2,076.10 Lacs for
nd ₹ 7,109.57 Lacs for year ended

egulation 33 of the Securities and
the Financial Results are available
(www.centuryply.com).

Century Plyboards (India) Limited
Sanjay Agarwal
Managing Director



NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
Phone:040-23547532, Email : investors@natcopharma.co.in
CIN : L24230TG1981PLC003201 website: www.natcopharma.co.in

Extract of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2019

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated				
		Quarter Ended		Year Ended	Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Refer Note-4	(Unaudited)	Refer Note-4	(Audited)	(Audited)
1	Revenue from operations	4,557	5,567	7,678	20,945	22,020
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	1,524	2,047	3,824	8,247	8,872
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	1,524	2,047	3,824	8,247	8,872
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	1,208	1,595	2,999	6,444	6,962
5	Total Comprehensive Income for the period attributable to owners of the parent	1,174	1,545	2,920	6,368	6,910
6	Equity share capital	365	368	369	365	369
7	Other equity				34,525	30,353
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)					
	a) Basic EPS	6.59	8.65	16.26	34.98	39.26
	b) Diluted EPS	6.58	8.63	16.21	34.87	39.13

Notes:

1. Summarized Unaudited Standalone Financial Results of the Company is as under:

Sl. No.	Particulars	Standalone				
		Quarter Ended		Year Ended	Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Refer Note-4	(Unaudited)	Refer Note-4	(Audited)	(Audited)
1	Total income from operations	4,163	5,319	7,290	19,863	21,085
2	Net Profit for the period before tax	1,544	2,064	3,764	8,474	8,876
3	Net Profit for the period after tax	1,234	1,620	2,961	6,671	6,982

2. The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on the Stock Exchange website: www.nseindia.com and www.bseindia.com and also on the Company's website www.natcopharma.co.in

3. The above financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on May 27, 2019.

4. The figures of the quarter ended 31 March 2019 and 31 March 2018 are balancing figures between audited figures in respect of the full financial year ended 31 March 2019 and 31 March 2018 and the published year to date figures upto the quarter ended 31 December 2018 and 31 December 2017 respectively, which were subjected to limited review by the statutory auditors.

5. The Board of Directors at their meeting held on May 27, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each.

Place: Hyderabad
Date: 27-05-2019

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

2019 మార్చి 31
 గా ఉన్నాయి.
 రాబంధం
 ంది.

కోట్లు

1. గ్యూస్ సరఫరా
 2. కోట్లకు, సహజ
 ంగ్ రూ. 587.53

ముఖ విలువ కలి
 రూ.1.77 తుది డివి
 క్షర్ణ బోర్డు నిర్ణయం
 9 ఆర్థిక సంవత్సరా
 ందు రూ.8.02కు
 కంపెనీ చెల్లించిన
 ధ్రం.

లో గ్యూస్ ఫైవ్ లైన్
 లదన ప్రణాళికను
 జింగ్ జై వీసీ
 రూ.8,34 కోట్లుగా
 కంపెనీ రూ.5,000
 తెలిపారు.

రాబంధం
 ంది.

కోట్ల నికర నష్టాన్ని
 సమాధు చేసింది.
 మొత్తం ఆదాయం రూ.976 కోట్ల నుంచి రూ.
 1,089 కోట్లకు చేరింది. 2018-19 పూర్తి ఆర్థిక
 సంవత్సరానికి నికర నష్టం రూ.7,206 కోట్లుగా
 నమోదైంది. అంతర్జాతీయ ఆర్థిక సంవత్సరం ఇది
 రూ.23,839 కోట్లుగా ఉంది. మొత్తం ఆదాయం
 రూ.4,684 కోట్ల నుంచి రూ.4,194 కోట్లకు
 తగ్గింది. ఇదిలా ఉంటే, ఈ నెల ప్రారంభంలో
 నేషనల్ కంపెనీ లా స్ట్రెబ్యూనల్ (ఎన్సీఎల్టీ)
 ఆర్కామ్ దివాలా ప్రక్రియకు అనుమతినిస్తూ
 తీర్పు చెప్పింది. దీంతో అనిల్ అంబానీ గ్రూపు
 నకు చెందిన ఆర్కామ్ తొలిసారిగా దివాలా ప్రక్రి
 యకు వెళుతున్న సంస్థగా నిలిచింది. ఆర్కామ్
 రూ.50,000 కోట్ల బకాయిల్ని బ్యాంకులకు చెల్లిం
 చాల్సి ఉంది. గత కొన్నేళ్లుగా ఈ సంస్థకు
 కష్టాలు ప్రారంభమయ్యాయి. దీంతో రెండేళ్ల
 నుంచి కార్యకలాపాలు నిలిపివేసింది. రిలయన్స్
 జియో ఇన్ఫ్రాస్ట్రక్చర్ ఆస్తులు విక్రయించి దివాలా
 ప్రక్రియ నుంచి బయటపడడామనుకుంటే,
 న్యాయపరమైన, ప్రభుత్వ అనుమతులు రాకపో
 వడంతో ఆర్కామ్ చేసిన ప్రయత్నాలు బెడిసికొ
 ట్టాయి. దీంతో స్థిరాస్తులు, స్పెక్ట్రమ్ ఆస్తులు విక్ర
 యించి రుణదాతల బకాయిలు తీరుస్తామన్న
 ఆర్కామ్ మాట నిలబెట్టుకోలేకపోయింది.
 వీఎస్కాలో షేరు ఎలాంటి మార్పు లేకుండా
 రూ.2.12 వద్ద ముగిసింది.

భామనకు	13.08	09.09.18	10.08	09.20
శ్రీయా ఇన్ఫ్రా	144.85	---	---	---
ఎన్హెచ్వీసీ	492.29	199.80	2186.25	1406.07
జీఈ పవర్	27.25	51.15	400.73	382.68
అదానీ ఫార్మ్	1314.19	929.06	3492.72	3487.29
హెచ్ఎఫ్ఎల్	2282.00	1987.00	19705.00	18284.00
హోటల్ లీలా	(29.82)	(15.80)	43.06	41.54
కోల్డ్రాట్ పాపాలివ్	197.59	188.77	1,146.63	1,085.06

నేటి బోర్డు సమావేశాలు

సన్ ఫార్మా, అరవింద్ ఫార్మా, ఎన్ఎండీసీ, పీఎన్వీ, హెచ్ఎంటీ,
 సైన్జెట్, ఎన్టీసీ ఇండియా, టీవీఎల్, అదానీ ట్రాన్స్మిషన్,
 గుజరాత్ అల్కలీస్, ఇర్కాన్ ఇంటర్నేషనల్, ఐటీఐ, జైవర్కా అసోసియేట్స్,
 కల్పేషిల్ డెవలప్మెంట్, లక్ష్మీ విలాస్ బ్యాంక్, మహా స్టీల్, మ్యాన్
 ఇండస్ట్రీస్, మిండా కార్పొరేషన్, నౌకరీ, రిలయన్స్ నేషనల్,
 జైడస్ వెల్ నెస్, తల్యాల్కార్స్

27న ఫారంగేటు అమ్మకం ధరలు (నెక్)				
(100కు రూపాయలలో)				
కో	హైదరాబాద్	317	వరంగల్	320
డి	విల్లరగా(జి.ఐ.ఐ.)	3.75	విశాఖపట్నం	325
గు	బెంగళూరు	375	చెన్నై	395
డు	28వ తేదీకి...		చిత్తూరు	388
	విజయవాడ/గోదావరి	323	నమకల్	390

ICICI LOMBAR	1117.40	(1130.50)	619017
IDEA CELLULAR	13.05	(12.85)	99540754
INTERGLOBE A	1662.15	(1621.75)	2697614
L&TFIN.HOLD	127.85	(128.10)	6191466
LUPIN	743.30	(763.30)	3299637
MARICO LIMIT	365.50	(363.15)	708539
MCDOWELL	536.35	(547.95)	1316062
MOTHERSON	116.15	(118.25)	23524587
MRF	56862.65	(57009.30)	6040
NHPC LTD	23.60	(23.05)	3188923
NMDC LTD	102.15	(97.80)	4751606
ORACLE FIN S	3406.55	(3418.45)	32669
P&G HYG&HEAL	10996.00	(10927.85)	1945
PAGE INDUSTR	19692.10	(21944.05)	342150
PETRONET LNG	245.00	(242.10)	2485867
PIDILITE IND	1229.00	(1237.60)	500765
PIRAMAL ENTE	2188.80	(2199.25)	394659
SAIL	50	(51.65)	23072280
SBI LIFE	398.90	(686.00)	1669747
SHREE CEMENT	21471.00	(20927.20)	44826
SHRIRAM TRAN	1138.25	(1107.60)	1215016
SIEMENS	1277.65	(1218.95)	906667
THE NEW INDI	165.90	(164.00)	59201
UNITED BREWE	1370.10	(1422.35)	671095

SMS PHARMA	61.50	(56.05)	1371
SOUTH BIO TE	1.05	(1.07)	1750
SREE RAYAL A	37.80	(37.75)	172003
SRI KPR INDU	14.65	(14.60)	900
SRINIVASA SH	27	(27.15)	170
STEEL EXCHAN	14.85	(14.45)	2726
SUJANA UNIVE	0.28	(0.28)	23063
SURANA TELE	3.80	(4.03)	7560
SURYALATA SP	135.70	(129.95)	7842
SUVEN PHARMA	272.20	(267.60)	26609
TAJ GVK HOTE	205.70	(193.30)	4247
TANLA	47.05	(46.55)	14028
TERA SOFTWARE	45.10	(42.15)	12053
TRANS BIOTEK	4.15	(4.16)	15022
VICEROY HOTE	2.87	(2.74)	6595
VIJAY TEXTIL	25.20	(27.30)	24755
VIMTA LABS	195.75	(196.75)	1233
VISAKA IND	404.90	(370.30)	17641
VISTA PHARMA	15.60	(15.30)	22372
VIVIMED LABS	22.75	(22.30)	13166
VST INDUS	3478.05	(3450)	239
YBRANT DIGIT	5.66	(5.77)	205810
ZENOTECH LAB	21.55	(20.55)	4977
ZENTECH	74	(74.55)	1230

NATCO Pharma Limited

Regd. Office: NATCO HOUSE, Road No.2, Banjara Hills, Hyderabad-500 034.
 Phone:040-23547532, Email : investors@natcopharma.co.in
 CIN : L24230TG1981PLC003201 website: www.natcopharma.co.in

Extract of Consolidated Audited Financial Results for the Quarter and Year Ended March 31, 2019

All amounts in Indian Rupees millions

Sl. No.	Particulars	Consolidated				
		Quarter Ended		Year Ended	Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Refer Note-4	(Unaudited)	Refer Note-4	(Audited)	(Audited)
1	Revenue from operations	4,557	5,567	7,678	20,945	22,020
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	1,524	2,047	3,824	8,247	8,872
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	1,524	2,047	3,824	8,247	8,872
4	Net Profit for the period after tax (after exceptional and/or extraordinary items) and non-controlling interests	1,208	1,595	2,999	6,444	6,962
5	Total Comprehensive Income for the period attributable to owners of the parent	1,174	1,545	2,920	6,368	6,910
6	Equity share capital	365	368	369	365	369
7	Other equity				34,525	30,353
8	Earnings Per Share (in Rupees) per ₹2/- share (non-annualised)					
	a) Basic EPS	6.59	8.65	16.26	34.98	39.26
	b) Diluted EPS	6.58	8.63	16.21	34.87	39.13

Notes:

- Summarized Unaudited Standalone Financial Results of the Company is as under:

Sl. No.	Particulars	Standalone				
		Quarter Ended		Year Ended	Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Refer Note-4	(Unaudited)	Refer Note-4	(Audited)	(Audited)
1	Total income from operations	4,163	5,319	7,290	19,863	21,085
2	Net Profit for the period before tax	1,544	2,064	3,764	8,474	8,876
3	Net Profit for the period after tax	1,234	1,620	2,961	6,671	6,982

- The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on the Stock Exchange website: www.nseindia.com and www.bseindia.com and also on the Company's website www.natcopharma.co.in
- The above financial results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on May 27, 2019.
- The figures of the quarter ended 31 March 2019 and 31 March 2018 are balancing figures between audited figures in respect of the full financial year ended 31 March 2019 and 31 March 2018 and the published year to date figures upto the quarter ended 31 December 2018 and 31 December 2017 respectively, which were subjected to limited review by the statutory auditors.
- The Board of Directors at their meeting held on May 27, 2019 have recommended an interim dividend of ₹ 1.25 per equity share of ₹2 each.

Place: Hyderabad
Date: 27-05-2019

for NATCO Pharma Limited
Sd/- V.C. Nannapaneni
Chairman & Managing Director

T. Suresh Hyderabad 28/5/19